Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS ANNOUNCES CONVERTIBLE DEBENTURE CONVERSION

Holders of Defence Therapeutics Inc.'s 8 per cent convertible debentures issued on Nov. 16, 2024, have converted all of the principal amount and the accrued interests thereof into an aggregate number of 2,607,600 common shares of the company upon maturity of debentures on Nov. 16, 2025.

In accordance with the terms of the debentures, the principal amount of $1,476,000 was converted into 2,460,000 shares at the conversion price of 60 cents per share and an aggregate amount of $118,080 of accrued interests was converted into 147,600 shares at 80 cents per share, totalling 2,607,600 shares for an aggregate amount of $1,594,080.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company developing and engineering the next generation of ADC (antibody-drug conjugate) products using its proprietary platform. The core of Defence Therapeutics platform is the Accum technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.

We seek Safe Harbor.